In brief: Liraglutide (INN: liraglutide) on the Longeva hub is a research GLP-1 sample supplied as a lyophilized powder with research use only (RUO) status. It is not Saxenda, not Victoza and not a finished prescription medicine.
Searches for "saxenda" and "liraglutide" often mix the trade name with the INN. Longeva supplies the molecule for laboratory protocols; batch quality is documented by a COA per LOT. The difference between brand and molecule is covered in the hub editorial Saxenda ↔ liraglutide; the RUO context of the brand sits on Incretin.
Saxenda, Victoza and the liraglutide molecule
Saxenda and Victoza are trademarks of finished injectable medicines containing liraglutide. They are registered as medicinal products with medical labelling, a different product class than an RUO lyophilizate. Longeva does not sell these brands.
A more detailed RUO breakdown on Incretin: Saxenda vs liraglutide.
GLP-1 research context
Liraglutide is described as a synthetic GLP-1 analogue. Clinical programmes studied it in controlled protocols, among them SCALE for body weight control. This is mechanistic context for the class, not a promise of an effect from an RUO vial.
Other GLP-1 samples on the hub:
Sample format
Lyophilized powder in a glass vial. Store dry, cool and protected from light in line with your laboratory SOP.
Batch verification by COA
- Find the LOT number on the vial and the packaging.
- Open the PDF in the COA archive.
- Check the substance, the methods (HPLC, identity) and the units of the results.
- Record the date of receipt and the link to the PDF in your log.
Further reading
Reference material. Not medical advice. The sample is intended for laboratory research only (RUO). Saxenda, Victoza, Ozempic and other names are trademarks of their respective owners.
